Bone health study for breast cancer survivors off bone medication
Part of Cancer, Skin clinical trials.
This study looks at bone complications in women who have finished treatment with denosumab (a bone-strengthening drug) and aromatase inhibitors (hormone therapy for breast cancer). It aims to learn more about what happens to bones after stopping these medications, which may help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with stage 0 to 3 breast cancer diagnosed at Memorial Sloan Kettering Cancer Center (MSKCC).
- You have no current evidence of cancer after treatment.
- You have been through menopause (your last period was at least 12 months ago).
- You have received at least 2 doses of denosumab (brand name Prolia or Xgeva) and then stopped taking it.
- You stopped taking aromatase inhibitors (like letrozole, anastrozole, or exemestane) either before or within 6 months of your last denosumab injection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called romosozumab, which may help strengthen bones and reduce fractures in people with breast cancer that has spread to the bones and who also have osteoporosis. If you are on hormone therapy and have weak bones, this could help protect your bones.
This study tracks bone health in breast cancer patients receiving hormone-blocking therapy (aromatase inhibitors, GnRH analogs, or tamoxifen). It aims to understand how these treatments affect bone mineral density.
This study tests whether denosumab, a medication that strengthens bones, can also improve muscle strength and insulin sensitivity in postmenopausal women with type 2 diabetes who take metformin.
This study tests an investigational injection called TST002 to see if it can help strengthen bones in postmenopausal women with osteoporosis or low bone mass. It may help reduce the risk of fractures.
This study tracks how a type of cancer treatment called anti-PD-1 immunotherapy affects bone strength over time. Researchers want to understand whether this treatment causes bone density loss and help develop ways to protect bones during cancer care.
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.